SCHEDULE 14A
                                 (RULE 14A-101)

                     INFORMATION REQUIRED IN PROXY STATEMENT

                            SCHEDULE 14A INFORMATION

                    PROXY STATEMENT PURSUANT TO SECTION 14(A)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

Filed by the Registrant |_|
Filed by a Party other than the Registrant |X|

Check the appropriate box:

|_|  Preliminary Proxy Statement
|_|  Confidential, for Use of the
      Commission Only (as permitted by
      Rule 14a-6(e)(2))
|_|   Definitive Proxy Statement
|_|   Definitive Additional Materials
|X|   Soliciting Material Pursuant to Rule 14a-12

                                 INTERCEPT, INC.
                (Name Of Registrant As Specified In Its Charter)

                                JANA PARTNERS LLC
    (Name Of Person(s) Filing Proxy Statement, If Other Than The Registrant)

Payment of Filing Fee (Check the appropriate box):
|X| No fee required.
|_| Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

     (1) Title of each class of securities to which transaction applies:
     (2) Aggregate number of securities to which transaction applies:
     (3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee
is calculated and state how it was determined):
     (4) Proposed maximum aggregate value of transaction:
     (5) Total fee paid:

|_| Fee paid previously with preliminary materials.
|_| Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number, or
the Form or Schedule and the date of its filing.



         (1) Amount Previously Paid:
         (2) Form, Schedule or Registration Statement No.:
         (3) Filing Party:
         (4) Date Filed:


                                       2






FOR IMMEDIATE RELEASE
For information contact MacKenzie Partners, Inc.:
Lawrence E. Dennedy or Robert C. Marese - (800) 322-2885

        JANA PARTNERS LLC FILES IN FEDERAL COURT TO FORCE INTERCEPT, INC.
                          TO HONOR SHAREHOLDERS RIGHTS

New York, New York --  April 26, 2004 - JANA  Partners  LLC  ("JANA")  announced
today that it has filed a counterclaim for injunctive and declaratory  relief in
Georgia federal court to force InterCept,  Inc. (NASDAQ - ICPT) ("InterCept") to
comply with its  longstanding  bylaw  provision  requiring  the election of four
directors to InterCept's  board of directors at InterCept's  2004 Annual Meeting
of Shareholders.  When JANA nominated four directors for election to InterCept's
six person board on April 5, 2004,  InterCept's  own bylaws provided that anyone
placed on the board to fill a vacancy  created by the  resignation of a director
would serve only until the next meeting of  shareholders,  which would result in
four directors being up for election this year. However,  after receiving notice
of JANA's nomination,  InterCept's board, without shareholder approval,  amended
the bylaw,  seeking to strip  shareholders  of this right.  In its court filing,
JANA also seeks  alternative  relief to bring other  proposals  to a vote at the
Annual Meeting.

JANA is also  seeking  the  court to  force  InterCept  to turn  over all of the
information  to JANA  that it is  entitled  to  under  Georgia  law in  order to
effectively  communicate  with its fellow  shareholders  in connection  with the
annual meeting.  While JANA made its information requests on April 5th and again
on April 8th,  InterCept to date has not turned over all of the information JANA
has requested.

In  a  letter  sent  to John W. Collins, Chairman and Chief Executive Officer of
InterCept,  today by JANA  Partners  Managing  Member Barry S.  Rosenstein,  Mr.
Rosenstein said:

          "We find the recent  actions taken by you and  management to deny the
          shareholders of InterCept their full voting and information  rights to
          be repugnant to the  standards of good  corporate  governance to which
          all public companies are bound. Because you and management seem not to
          be aware,  we would like to remind you that laws  giving  shareholders
          the right to vote,  providing  shareholders with access to information
          about  the  company  and  preventing   management   from   entrenching
          themselves at the expense of shareholders  are in place because public
          companies  like  intercept  are to be run for  the  benefit  of  their
          shareholders,  not for the benefit of you,  the board of  directors or
          management."

Mr. Rosenstein went on to say in his letter that:

          "Your and  management's  response in almost every case has been solely
          dedicated to denying or delaying  these basic  shareholder  rights and
          therefore  today we have filed in Georgia  federal  court to force you
          and   management   to  honor   the   Company's   obligations   to  its
          shareholders."

The  complete  text of Mr.  Rosenstein's  letter  sent  today to Mr.  Collins is
attached to this press release.

BACKGROUND

In October,  2003,  InterCept  announced  that its Chairman and Chief  Executive
Officer,  John W. Collins,  intended to make an offer to take InterCept private,
and that the  InterCept  board of  directors  had  formed a special  independent
committee to evaluate the  possible  sale of the Company.  On December 12, 2003,
InterCept  announced  that Mr.  Collins  would  not be  making an offer but that
"several  third  parties  initiated  contact  with  the  special  committee  and
expressed  interest in InterCept,  and the special  committee will be evaluating
those indications of interest." Less than two months later, InterCept's board of
directors  terminated  the sale  process and  dissolved  the special  committee.
Following the decision not to continue  with the sale  process,  on February 13,
2004, two of the three independent directors on the special committee,  Boone A.
Knox (the then Vice  Chairman)  and Jon R.  Burke,  resigned  as a result of the
decision.

If elected,  the  directors  nominated  by JANA would  constitute  a majority of
InterCept's  six-person  board and  intend to  immediately  engage a  nationally
recognized investment banking firm to conduct a full and fair review of the best
value-maximizing options for shareholders, including sale of the company.

CERTAIN INFORMATION CONCERNING PARTICIPANTS

JANA Partners LLC manages  securities  portfolios  with assets of  approximately
$1.4 billion and  currently  owns  1,619,937  shares  (approximately  8%) of the
common stock of InterCept.

The following individuals have consented to being nominated by JANA Partners LLC
for election as directors of  InterCept at  InterCept's  2004 Annual  Meeting of
Shareholders:

     o Barry S. Rosenstein,  45, has been a Managing Member of JANA Partners LLC
     since 2001. From 1993 to 2001, Mr. Rosenstein was a Principal of Sagaponack
     Partners, L.P., a private equity fund.
     o Gary Claar,  37, has been a Managing  Member of JANA  Partners  LLC since
     2001.  From 1999 to 2001,  Mr. Claar was a Principal  of Marathon  Advisors
     LLC, an investment fund.
     o Kevin J. Lynch, 35, has been a Principal of JANA Partners LLC since 2001.
     From 1999 to 2001, Mr. Lynch was an Investment Analyst at Sagaponack
     Partners, L.P.
     o Marc Weisman, 51, has been a Principal of Sagaponack Partners, L.P. for
     more than the past five years.

The principal  business  address of Mr. Claar is 200 Park Avenue,  New York, New
York 10166. The principal  business  address of Mr.  Rosenstein and Mr. Lynch is
201 Post Street,  Suite 1000, San  Francisco,  California  94108.  The principal
business address of Mr. Weisman is 645 Fifth Avenue, New York, New York 10022.

Each of these  nominees  has  agreed,  if  elected,  to serve as a  director  of
InterCept. JANA Partners does not expect that any of its nominees will be unable
to stand  for  election  or  serve as a  director,  but if any  vacancy  in JANA
Partners' slate occurs for any reason (including if InterCept makes or announces
any changes to its bylaws or takes or announces any other action that has, or if
completed would have, the effect of  disqualifying  any or all of JANA Partners'
nominees),  JANA Partners will vote for the substitute candidate(s) nominated by
JANA Partners in compliance  with the rules of the SEC and any other  applicable
law and, if applicable, InterCept's bylaws.

JANA Partners LLC intends to file a proxy statement and other relevant documents
with the SEC in support of the election of Messrs. Rosenstein,  Claar, Lynch and
Weisman to the InterCept board.  INVESTORS ARE URGED TO READ THE PROXY STATEMENT
WHEN IT BECOMES  AVAILABLE AND ANY OTHER RELEVANT  DOCUMENTS  FILED WITH THE SEC
BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.  You will be able to obtain the
documents  free of charge at the SEC's website,  www.sec.gov.  JANA Partners LLC
and  Messrs.  Rosenstein,   Claar,  Lynch  and  Weisman  may  be  deemed  to  be
participants in the  solicitation of proxies from the  shareholders of InterCept
in connection with the annual meeting. Information about these participants will
be set forth in the proxy  statement  filed by JANA  Partners  LLC with the SEC.
Investors may obtain additional  information by reading the proxy statement when
it becomes available.






[GRAPHIC OMITTED]

                                               April 26th, 2004

John W. Collins
Chairman/Chief Executive Officer
InterCept, Inc.
3150 Holcomb Bridge Road
Suite 200
Norcross, GA 30071

Dear Mr. Collins,

     We find  the  recent  actions  taken  by  you,  the  board of directors and
management  to  deny  the  shareholders  of  InterCept  their  full  voting  and
information rights to be repugnant to the standards of good corporate governance
to which all public companies are bound.  Because you and management seem not to
be aware, we would like to remind you that laws giving shareholders the right to
vote,  providing  shareholders  with access to information about the company and
preventing management from entrenching themselves at the expense of shareholders
are in place  because  PUBLIC  COMPANIES  LIKE  INTERCEPT  ARE TO BE RUN FOR THE
BENEFIT  OF  THEIR  SHAREHOLDERS,  NOT FOR THE  BENEFIT  OF YOU,  THE  BOARD  OF
DIRECTORS OR MANAGEMENT.

     We have  requested  the  following  rights  to  which  we are  entitled  as
shareholders  of InterCept:  the right to nominate  four  directors as set forth
under  InterCept's  own  bylaws,  the right to a full and  complete  list of our
fellow  shareholders  so that we may contact them and the right to certain books
and records of the company so that we may gather the  necessary  information  to
conduct an informative and fair proxy contest. Your and management's response in
almost every case has been solely  dedicated to denying or delaying  these basic
shareholder  rights and  therefore  today we have filed suit in Georgia  federal
court to  force  you and  management  to honor  InterCept's  obligations  to its
shareholders.  We learned  today that you have finally  agreed to turn over some
information,  knowing as you must that the court  this week would have  required
you to do so anyway, although we have not yet received such information.

     In  light  of InterCept's actions, we feel compelled to remind both you and
the other  members of the board that  directors of a public  company can be held
personally  liable for breaches of fiduciary duty, and we would urge each of you
to carefully  consider  not only your past  actions but any further  efforts you
might take to frustrate our efforts to bring accountability to InterCept's board
and to maximize the value of all of its shareholders' investments.

     THE RIGHT TO NOMINATE DIRECTORS AS PROVIDED BY INTERCEPT'S OWN BYLAWS

     InterCept's  own  bylaws,  up until April 14th, 2004, provided that
"A  director  elected to fill a vacancy  shall hold  office  only until the next
election of directors by the  shareholders."  Because two directors of InterCept
resigned  last  February  as a result of the  board's  decision  to  discontinue
evaluating  a sale of the company,  this would mean that the board's  handpicked
directors who filled these vacancies would be up for election  together with the
two directors whose terms also expire at the annual meeting, creating a total of
four open  seats on the board.  Management  now has  informed  us,  without  any
apparent  embarrassment,  that we have somehow created "confusion" by seeking to
follow the letter of the company's own bylaws in nominating  directors.  We find
these comments to be the height of hypocrisy and misdirection.

     Moreover,  while the board has been  content  to let this  provision  stand
since 1998, on Spril 14th,  2004,  without the approval of shareholders  despite
the fact that a shareholders  meeting is coming up, the board amended the bylaws
to remove the "confusion"  that would have allowed  shareholders to exercise the
rights to which they have been led to believe they are entitled by the company's
own bylaws. if this provision of the bylaws has been allowed to stand for almost
six years,  what possible purpose could there be for "fixing" it now, on the eve
of an election, other than management entrenchment?

     THE RIGHT TO CONTACT FELLOW SHAREHOLDERS

     The right to demand shareholder information is one of the most basic rights
held by  shareholders  because it provides them with a voice by allowing them to
contact  other  concerned  shareholders.   In  addition  to  rights  granted  to
shareholders  under Georgia common law, under the Georgia  Business  Corporation
Code shareholders  holding more than 2% of a Georgia public company are entitled
to a record of the company's  shareholders  and other  information.  Although we
hold well over the required  percentage of InterCept's  common stock to exercise
this right,  management has denied us this basic right with trumped-up  requests
for unnecessary additional information.  Although finally, on the eve of a court
hearing,  you have agreed to provide us with some of this  information,  we have
yet to receive it and thus can not determine whether it will be sufficient.

      THE RIGHT TO INSPECT THE COMPANY'S BOOKS AND RECORDS

      We  have  requested  certain  of  InterCept's  books and records, to which
shareholders are entitled under the law,  including  information that would shed
light on the board of directors'  abrupt  decision to shut down the sale process
it began last year.  Given the many  questions  surrounding  this  decision,  we
believe  it  is  important  that  InterCept's  shareholders  get  some  type  of
explanation  for the board's  motivation.  This is all the more important in the
context of the  upcoming  election of  directors,  prior to which we believe the
company's  shareholders  should be  presented  with all of the  facts.  While we
suspect  there are good  reasons that you and the board do not want to turn over
this information,  we remind you once again that this is what being on the board
of a public company entails,  THAT IS, BEING  ACCOUNTABLE TO THE SHAREHOLDERS OF
THE COMPANY.

     While we  are  disappointed in the actions taken by you, management and the
board,  we are not  surprised,  given that this is hardly the first time we have
witnessed  management  entrenchment  activity  and  failure  to act in the  best
interests of the shareholders at InterCept.  Specifically, the facts surrounding
the  aforementioned  decision  by the board to  abruptly  end the sale  process,
despite  receiving  several  indications  of  interest  at what we believe  were
meaningful  premiums,  make very clear that the board  (excluding  of course the
independent  directors  who  quit as a result  of the  decision)  had only  been
interested  in selling to you, not in realizing  the maximum  value of InterCept
for its  shareholders.  We also find it very  troubling  that shortly before you
announced  your  plan to make an offer to take the  company  private,  InterCept
issued preferred stock to investors  granting  extraordinary  rights such as the
right to block any amendment to the company's charter or bylaws and to block any
sale of the  company,  even  should a  majority  of  shareholders  support  such
actions,  all  in  exchange  for  only  $10  million,  or  approximately  2%  of
InterCept's  total  assets  at the  time.  To put it  another  way,  holders  of
preferred representing approximately 3% of InterCept's stock now have more power
than a majority of InterCept's shareholders.

     You  seek  to make a great deal of the fact in your public comments that we
are in the business of making  investments.  It might  surprise you to know that
all of your  shareholders  have made an investment in your company,  and whether
they are looking for a "quick buck" or just a fair return,  they have a right to
protect their  investment  from management  entrenchment  and obstruction of the
voting franchise.  InterCept shareholders wondering who would do the best job of
maximizing the value of their  investment  might also be interested to know that
since the  inception  of our fund,  we have  delivered an  annualized  return of
30.4%,  during a period in which the S&P  Index's  annualized  return fell by 1%
(but then again, we have focused only on what's best for our investors).

     Mr.  Collins,  all  we  have  asked for is that the management of InterCept
allow its  shareholders  to exercise  their voting rights in a fairly  conducted
election.  Let's just say it: you and  management  are fighting this because you
are well aware that, if given the chance,  the  shareholders  of InterCept  will
replace you and a majority of the board.  Rest assured  however that we will not
permit you to deny your shareholders their rights.

                                      Sincerely,

                                      JANA Partners LLC


                                      /s/ Barry S. Rosenstein
                                      Barry S. Rosenstein
                                      Managing Member

CC: THE OTHER MEMBERS OF THE BOARD OF DIRECTORS OF INTERCEPT
         Dr. James A. Verbrugge
         Mark Hawn
         John D. Schneider, Jr.
         Glenn W. Sturm
         Arthur G. Weiss